现代医药卫生2026，Vol.42Issue(1)：53-57,5.DOI:10.3969/j.issn.1009-5519.2026.01.010
不同剂量替加环素治疗CR-KP肺炎效果研究
Efficacy of different doses of tigecycline in the treatment of CR-KP pneumonia
摘要
Abstract
Objective To compare the clinical efficacy and safety of different doses of tigecycline in the treatment of Carbapenem resistant Klebsiella pneumoniae(CR-KP)pneumonia.Methods A total of 96 pa-tients with CR-KP pneumonia admitted to Zhumadian Central Hospital,Henan Province,from May 2021 to June 2023 were enrolled in this prospective,randomized,controlled study.They were randomly assigned via computer-generated sequence to either the standard-dose group(n=48,tigecycline 50 mg every 12 hours)or the high-dose group(n=48,tigecycline 100 mg every 12 hours).Treatment efficacy,prognostic outcomes,and safety were compared between the two groups.Results The bacterial clearance rate in the high-dose group was 93.75%(45/48),numerically higher than that in the standard-dose group[87.50%(42/48)],without reaching statistical significance(P>0.05).No significant differences were found between the two groups in the following outcomes(P>0.05):bacterial replacement rate[8.33%(4/48)in the high-dose vs.10.42%(5/48)in the standard-dose group],bacterial reinfection rate[4.17%(2/48)vs.8.33%(4/48)],and 28-day mortality[2.08%(1/48)vs.6.25%(3/48)].Furthermore,no significant intergroup differences were ob-served in post-treatment inflammatory markers,including high-mobility group box 1 protein[(20.33±5.16)ng/L vs.(21.45±5.36)ng/L],soluble triggering receptor expressed on myeloid cells-1[(102.45±20.77)μg/L vs.(105.46±20.74)μg/L],and C-reactive protein[(7.62±1.38)mg/L vs.(8.02±1.77)mg/L],or in T-lymphocyte subsets CD3+[(65.33±10.27)%vs.(62.44±10.61)%],CD4+[(42.25±10.31)%vs.(40.35±10.33)%],and the CD4+/CD8+ratio(2.11±0.46 vs.1.95±0.78).However,the high-dose group had a sig-nificantly longer hospital stay[(35.25±5.18)d vs.(32.44±5.16)d,P<0.05]and a significantly higher inci-dence of tigecycline-related adverse reactions[20.83%(10/48)vs.4.17%(2/48),P<0.05].Conclusion Tigecy-cline is an effective treatment for reducing inflammation and improving immune function in patients with CR-KP pneumonia.Compared with the standard-dose,high-dose tigecycline has a higher bacterial clearance rate,but increasing the dose may increase the risk of drug side effects and prolong hospitalization.关键词
耐碳青霉烯肺炎克雷伯菌肺炎/替加环素/用药剂量/治疗结果Key words
Carbapenem resistant Klebsiella pneumoniae pneumonia/Tigecycline/Drug dosage/Treatment outcome分类
医药卫生引用本文复制引用
申国庆,王运,刘辉,甘文云,徐敬敬,麻恒翔,王文娟..不同剂量替加环素治疗CR-KP肺炎效果研究[J].现代医药卫生,2026,42(1):53-57,5.基金项目
河南省医学科技攻关项目(LHGJ202001327). （LHGJ202001327）
